TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02556853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Determination of tube position by ultrasound.
Description: After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by ultrasound (Sonoscape S6®). The ultrasound probe will be placed between the 2nd and 3rd intercostal space at the level of the midclavicular line parallel to the line. The probe will be slightly moved or tilted until the pleural line is identified. If lung sliding is identified then the ventilation of the lung will be considered adequate. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
Study: NCT02688361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluimucil® 2% solution
Description: Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine 2% solution
Description: Participants will be orally administered with 10ml of 2% oral solution of Acetylcysteine (test)
Study: NCT03670433

Intervention type: OTHER
Intervention: Cost analysis of medication reconciliation
Description: 1. The MR at entry is performed by the pharmaceutical team as soon as possible after admission. The sequences of the medical conciliation are attributed to the health professionals according to the recommendations of the French National Authority for Health (HAS).~2. The MR at the discharge is carried out in collaboration between the pharmaceutical and medical teams. It associates the patient through pharmaceutical interview and relies on the sharing of informations related to the patient's medical treatments. These informations are synthesized in an output conciliation sheet transmitted in real time by secure messaging to the attending physician and the dispensing pharmacist. In parallel, the liaison letter and the patient discharge order are generated in order to guarantee a perfect homogeneity between all the documents transmitted at the patient's exit. MR sequences are attributed to health professionals according to the recommendations of the HAS.
Study: NCT03930511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: According to patients' needs and physician referral, individually tailored treatments of respiratory physiotherapy, functional training, exercise training and patient education
Study: NCT01390519

Intervention type: OTHER
Intervention: everolimis
Study: NCT04007679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: Pain neuroscience education (PNE) was conducted in physical conditions similar to the university classrooms where the study was performed. The sessions were conducted as 70-minute didactic group lessons with the same content held in separate sessions for students in each class. PowerPoint (Microsoft Corp., Redmond, WA, USA) presentations prepared by the instructor were used in all sessions. Metaphors, anecdotes, graphics, and pictures were used in an attempt to convey the information and messages about pain physiology and theory more permanently and effectively. In the PNE sessions, it was explained that the nervous system can be overprotective and that in addition to the sensitivity of the central nervous system, nociceptive transmission can be affected by an individual's thoughts, beliefs, and surroundings. At the end of the session, the students were given time to ask questions, but group discussion was limited to 15 minutes due to time restrictions.
Study: NCT02556853

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Determination of tube position by auscultation.
Description: After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by auscultation of the upper lung fields. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
Study: NCT01289457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 1-3) of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 1-3) of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 1-3) of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 1 g/m2 by vein over approximately 2 hours daily for 5 days (days 1-5) for a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 1 g/m2 by vein over approximately 2 hours daily for 5 days (days 1-5) for a 28 day cycle.
Study: NCT03198169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atteris Antimicrobial Skin and Wound Cleanser
Description: Wounds will be cleansed with either the experimental wound cleanser or a placebo and will then be covered with standard of care wound dressings.
Study: NCT01878435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS reminder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS reminder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS reminder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Travel subsidy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Travel subsidy 2
Study: NCT00938782

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sedline
Study: NCT01522339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE OPTIMA MR430s with HDX/GE Electronics
Description: MRI scan(s) for no longer than 60 minutes
Study: NCT03633903

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Mindfulness based stress reduction adapted for teens is a mindfulness intervention designed to aid adolescents in understanding stress, better coping with stress, and promoting resilience
Study: NCT03165383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine (Transversus Abdominis Plane Block)
Description: Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly up to 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Patient Controlled Analgesia (PCA) Morphine
Description: PCA Intravenous Morphine 1 milligram bolus on demand was given as rescue analgesia up to 24 hours.
Study: NCT01883765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback active

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neurofeedback active
Study: NCT03198169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atteris Antimicrobial Barrier Film Dressing
Description: Wounds will be covered with either the experimental barrier film dressing or a placebo and will then be covered with standard of care wound dressings.
Study: NCT01289457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 1 g/m2 by vein over approximately 2 hours daily for 5 days (days 1-5) for a 28 day cycle.
Study: NCT03950674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion
Study: NCT01289457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 by vein over approximately 30 minutes daily for 5 days (days 1-5).
Study: NCT03198169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atteris Antimicrobial Barrier Film Dressing
Description: Wounds will be covered with either the experimental barrier film dressing or a placebo and will then be covered with standard of care wound dressings.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atteris Antimicrobial Barrier Film Dressing
Description: Wounds will be covered with either the experimental barrier film dressing or a placebo and will then be covered with standard of care wound dressings.
Study: NCT03950674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion
Study: NCT02119091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Study: NCT00846287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperpolarized Helium-3
Description: Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the intervention (drug or placebo) will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyperpolarized Helium-3
Description: Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the intervention (drug or placebo) will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
Study: NCT00846287

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will inhale a placebo (nebulized saline) with no drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aformoterol
Description: Subjects will receive the drug arformoterol prior to scanning
Study: NCT04728867

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: to compare the educational effectiveness of various educational tools
Description: This prospective, randomized, blinded study is designed to compare the educational effectiveness of various educational tools including the surgical textbook, animation, and cadaveric videos in laparoscopic rectal surgery among board-certificated surgeons.
Study: NCT02692820

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The probiotic capsule contains the two probiotics Lactobacillus rhamnosus GR-1 (GR-1) and Lactobacillus reuteri RC-14 (RC-14). The product contains freeze-dried bacteria and excipients in a gelatin capsule;

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: The placebo contains excipients alone in a gelatin capsule
Study: NCT01323673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol propionate 0.05%
Description: 2 times a day, 14 total days study treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle / Placebo
Description: 2 times a day, 14 total days of study treatment
Study: NCT00366834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant (GW679769) oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant (GW679769) oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant (GW679769) oral tablets
Study: NCT00366834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant (GW679769) intravenous
Study: NCT04728867

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: to compare the educational effectiveness of various educational tools
Description: This prospective, randomized, blinded study is designed to compare the educational effectiveness of various educational tools including the surgical textbook, animation, and cadaveric videos in laparoscopic rectal surgery among board-certificated surgeons.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: to compare the educational effectiveness of various educational tools
Description: This prospective, randomized, blinded study is designed to compare the educational effectiveness of various educational tools including the surgical textbook, animation, and cadaveric videos in laparoscopic rectal surgery among board-certificated surgeons.
Study: NCT01590992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure-based psychotherapy for somatic symptoms
Description: Application of different types of exposure-based psychotherapeutic interventions (behavioral therapy), adapted for subjects with somatic symptoms (Somatoform Disorders/Functional Somatic Syndromes)
Study: NCT03950674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid 350-1000 μg
Description: Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
Study: NCT01590992

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation therapy
Description: Progressive muscle relaxation (Jacobson)
Study: NCT01070043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg/Valsartan 80 mg
Description: Combination therapy of Amlodipine/Valsartan 5mg/80mg one dosage daily with one single tablet size for 8 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan
Description: For run-in period, Valsartan 80 mg daily in one dosage with one single tablet size for 4 weeks.~Monotherapy for double blind treatment period in one dosage (Valsartan 160mg) daily with one single tablet size for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: For run-in period, Valsartan 80 mg daily in one dosage with one single tablet size for 4 weeks.~Monotherapy for double blind treatment period in one dosage (Valsartan 160mg) daily with one single tablet size for 8 weeks
Study: NCT02259218

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04368273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: a new treatment drug combined radical radiotherapy concurrent chemotharpy
Study: NCT03276819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Samples collection
Description: OPML biopsy or resection, biopsy of normal oral mucosa, surgical specimen of HNSCC, saliva samples, buccal brushes, blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Samples collection
Description: OPML biopsy or resection, biopsy of normal oral mucosa, surgical specimen of HNSCC, saliva samples, buccal brushes, blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Samples collection
Description: OPML biopsy or resection, biopsy of normal oral mucosa, surgical specimen of HNSCC, saliva samples, buccal brushes, blood samples

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological and Sociological evaluation
Description: Cohort B ....

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive and sustained smoking cessation program
Description: Evaluation of efficacy of the smoking cessation program (intensive and sustained versus minimal)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco and alcohol status follow-up
Description: Evaluation of the tobacco and alcohol status all along the study (questionnaires)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco and alcohol status follow-up
Description: Evaluation of the tobacco and alcohol status all along the study (questionnaires)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco and alcohol status follow-up
Description: Evaluation of the tobacco and alcohol status all along the study (questionnaires)
Study: NCT00753779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colesevelam HCl tablets, and simvastatin tablets
Description: colesevelam HCl tablets, 6/day simvastatin tablet, 1/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: simvastatin tablets and colesevelam HCl placebo
Description: simvastatin tablet, 1/day; Welchol placebo tablets, 6/day
Study: NCT05337293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPE-HF Partnership Intervention
Description: Participants were trained to use a 4-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems experienced in the home over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention was to move HF patients toward a positive problem orientation and use of rational problem-solving strategies that support greater HF self-care and reduce depression. The COPE-HF Partnership Intervention consisted of 1 home visit and 7 follow-up telehealth sessions led by a registered nurse interventionist.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Attention
Description: Participants in the attention group received a sham intervention that consisted of scheduled telephone calls consistent with the timing of that received by the intervention group. During these calls, basic information was gathered on key areas of heart failure self-care management and the frequency of healthcare usage. No intervention or education was provided.
Study: NCT01484054

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with print and PVP for dark eyes (EAPVPDE)
Description: A daily disposable contact lens
Study: NCT03950674

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid 350-1000 μg
Description: Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
Study: NCT01484054

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with print and PVP for dark eyes (EAPVPDE)
Description: A daily disposable contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A control lens (EADE)
Description: A marketed daily disposable contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A control lens (EADE)
Description: A marketed daily disposable contact lens
Study: NCT03950674

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12 1000 μg
Description: Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 1000 μg
Description: Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Description: For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
Study: NCT00764491

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Structural Allograft Spacer
Description: Following disc space preparation the spacer is placed in accordance with cleared labeling and supplemental instrumentation is provided as an adjunct to fixation.
Study: NCT01883765

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neurofeedback sham
Study: NCT03950674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg
Description: For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline solution
Description: IV infusion
Study: NCT00709137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone
Description: tablet form. doses used range from 12.5-50mg po QDAY. Total duration would be until completion or study or medication intolerance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amiloride
Description: amiloride 2.5-10 mg po QDAY. Duration until completion of study or until tolerance
Study: NCT02134639

Intervention type: PROCEDURE
Intervention: 68Ga-DOTATOC PET-CT Imaging
Study: NCT00764491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OptiMesh 1500S
Description: Following disc space preparation the OptiMesh is deployed and filled in accordance with study surgical technique and supplemental instrumentation is provided as an adjunct to fixation.
Study: NCT02634281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
Study: NCT00522223

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Participants who are treated with radiation therapy: Questionnaires 5 times.~Participants who undergo a radical hysterectomy: Questionnaires 4 times.
Study: NCT02445846

Intervention type: DEVICE
Intervention: dual HIV/syphilis rapid diagnostics tests
Study: NCT00002923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN5500
Study: NCT02634281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment